Bristol Myers Squibb Co. and Celgene Corp. have described MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of inflammation, cancer, fibrosis, autoimmune disorders, cardiovascular disorders, metabolic disorders and cerebrovascular disorders.